advertisement
Abstract #26466 Published in IGR 12-3
Use of bevacizumab as an additional strategy in angle closure glaucoma--case report
Helemejko I; Jurowska-Liput JKlinika Oczna 2010; 112: 61-62
We report the use of bevacizumab (Avastin) as an additional strategy in angle closure glaucoma based on the case of 47 years old male qualified to cataract removal as anti-glaucoma procedure, in whom we observed iris and lens neovascularization. As a first step we administered 1.25 mg of bevacizumab into the anterior chamber. Iris as well as lens neovasularization completely disappeared after 48 hours later. Finally after lens removal we achieved deeper anterior chamber, reduction and stabilization of intraocular pressure without necessity of administration hipotensive agents, and improvement of visual acuity.LA: Polish
I. Helemejko. Katedry i Kliniki Okulistyki Akademii Medycznej we Wroclawiu. jjliput@op.pl
Classification:
9.3.2 Chronic primary angle closure glaucoma (pupillary block) (Part of: 9 Clinical forms of glaucomas > 9.3 Primary angle closure glaucomas)
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)